High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal.
Antiretroviral
Decentralization
Pediatric HIV
Senegal
Viral resistance
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
05 02 2019
05 02 2019
Historique:
received:
12
10
2018
accepted:
29
01
2019
entrez:
7
2
2019
pubmed:
7
2
2019
medline:
23
2
2020
Statut:
epublish
Résumé
In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even though the emergence of viral resistance, particularly among children in Africa, is a well-known phenomenon. This study aimed to assess the virological status of HIV-infected children in all decentralized facilities to help improve access to quality care. A cross-sectional epidemiological and virological study was conducted in all of Senegal's regions, except Dakar, between March and June 2015 and sought to include all HIV-infected children and adolescents (0-19 years), treated or not with ARVs. Socio-demographic and clinical data and a blood sample on blotting paper were collected for children from treatment sites. Samples were routed on public transportation, assisted by a network of community health workers. A viral load (VL) assay was performed for each child, followed by genotyping when it exceeded 1000 copies/mL (3 log Of the 851 identified children, 666 (78%) were enrolled in the study. Half of the children were girls, and the average age was 8 years (6 months-19 years). Most of the children (96.7%) were infected with HIV-1, and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic regimen. The median duration of time on ART was 21 months (1-129). VL was measured for 2% of children before this study. Almost two-thirds (64%) of the children are experiencing virological failure. Among them, there was resistance to at least one drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% to two out of three. For nearly one-third of the children presenting resistance, none of the three drugs of the treatment was active. Factors associated with virological failure were male sex, follow-up by a generalist rather than a specialist, and treatment interruptions. We observed a high level of virological failure and a high percentage of viral resistance among children receiving health care in decentralized facilities in Senegal.
Sections du résumé
BACKGROUND
In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even though the emergence of viral resistance, particularly among children in Africa, is a well-known phenomenon. This study aimed to assess the virological status of HIV-infected children in all decentralized facilities to help improve access to quality care.
METHODS
A cross-sectional epidemiological and virological study was conducted in all of Senegal's regions, except Dakar, between March and June 2015 and sought to include all HIV-infected children and adolescents (0-19 years), treated or not with ARVs. Socio-demographic and clinical data and a blood sample on blotting paper were collected for children from treatment sites. Samples were routed on public transportation, assisted by a network of community health workers. A viral load (VL) assay was performed for each child, followed by genotyping when it exceeded 1000 copies/mL (3 log
RESULTS
Of the 851 identified children, 666 (78%) were enrolled in the study. Half of the children were girls, and the average age was 8 years (6 months-19 years). Most of the children (96.7%) were infected with HIV-1, and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic regimen. The median duration of time on ART was 21 months (1-129). VL was measured for 2% of children before this study. Almost two-thirds (64%) of the children are experiencing virological failure. Among them, there was resistance to at least one drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% to two out of three. For nearly one-third of the children presenting resistance, none of the three drugs of the treatment was active. Factors associated with virological failure were male sex, follow-up by a generalist rather than a specialist, and treatment interruptions.
CONCLUSIONS
We observed a high level of virological failure and a high percentage of viral resistance among children receiving health care in decentralized facilities in Senegal.
Identifiants
pubmed: 30722780
doi: 10.1186/s12887-019-1420-z
pii: 10.1186/s12887-019-1420-z
pmc: PMC6362577
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Références
PLoS One. 2015 Dec 14;10(12):e0144057
pubmed: 26658814
Clin Infect Dis. 2016 Dec 15;63(12):1645-1654
pubmed: 27660236
Clin Infect Dis. 2015 Nov 1;61(9):1453-61
pubmed: 26157050
Pan Afr Med J. 2013 Jun 30;15:80
pubmed: 24171063
Afr J AIDS Res. 2016 Sep;15(3):301-9
pubmed: 27681154
Medicine (Baltimore). 2017 Mar;96(10):e6282
pubmed: 28272247
BMC Infect Dis. 2012 Nov 22;12:317
pubmed: 23171203
J Clin Microbiol. 2013 Feb;51(2):578-84
pubmed: 23241378
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):e83-e89
pubmed: 27846074
BMC Pediatr. 2010 Jul 30;10:54
pubmed: 20673355
AIDS. 2017 Jan 2;31(1):61-70
pubmed: 27677163
Lancet Infect Dis. 2011 Oct;11(10):769-79
pubmed: 21872531
AIDS Res Hum Retroviruses. 2013 Feb;29(2):242-9
pubmed: 22860571
Lancet Infect Dis. 2018 Apr;18(4):379-380
pubmed: 29582762
J Int AIDS Soc. 2016 Apr 27;19(1):20683
pubmed: 27125320
Lancet Infect Dis. 2018 Mar;18(3):346-355
pubmed: 29198909
Clin Infect Dis. 2009 Dec 15;49(12):1915-27
pubmed: 19916798
J Clin Microbiol. 2014 Feb;52(2):578-86
pubmed: 24478491
BMC Infect Dis. 2013 Jan 02;13:1
pubmed: 23280237
AIDS. 2014 Mar;28 Suppl 2:S161-9
pubmed: 24849476
Med Sante Trop. 2016 Jan-Mar;26(1):10-4
pubmed: 26986242